gas and glp 1 Signaling Pathways of the GLP-1 Receptor: Activation via Gαs Glucagon-like peptide-1: Trends in Endocrinology
Description
In the phase 2 trial, 41% to 63% of participants receiving cagrilintide (0.3 to 4.5 mg) experienced gastrointestinal adverse events, compared to 32% with placebo
2010 Sep-Oct;17(5):487491
Are GLP-1s better than metformin
Specifically, robust and consistent protective effects were observed for schizophrenia and anxiety disorders, as evidenced by significant associations across all datasets analyzed
